Perifosine

Confirm delete?

Perifosine

Zoom

Cat No: 10008112

Biochemicals - Lipids

Alkylphospholipids are a class of antineoplastic compounds that display potent antiproliferative activity in several in vitro and in vivo human tumor models. Perifosine is an alkylphospholipid that induces apoptotic cell death in a variety of tumor cel...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

4-[[hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethyl-piperidinium, inner salt

Correlated keywords:

antitumors alkylphospholipids apoptosis leukemia prostate carcinomas cyclin kinases cancers antineoplastics antiproliferative cells death inhibits inhibition inhibitor PC-3 Akt p21WAF1 squamous p53-independent activation expression

Product Overview:
Alkylphospholipids are a class of antineoplastic compounds that display potent antiproliferative activity in several in vitro and in vivo human tumor models. Perifosine is an alkylphospholipid that induces apoptotic cell death in a variety of tumor cell lines.{14118} Apoptosis is induced in a time- and dose-dependent manner in U937 and Jurkat T human leukemia cell lines but not in normal vascular endothelial cells. Perifosine causes inhibition of PC-3 prostate carcinoma cell growth (growth inhibition (GI50) = 5 µM at 24 h) and is associated with rapidly decreased Akt activation.{13739} In addition, perifosine induces p21WAF1 expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest.{14119}

Size	1 mg
Shipping	dry ice
CAS Number	157716-52-4
Molecular Formula	C₂₅H₅₂NO₄P
SMILES	CCCCCCCCCCCCCCCCCCOP(OC1CC[N+](C)(C)CC1)([O-])=O
Molecular Weight	461,7
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2919.90
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.